renal cell carcinoma
Conditions
Interventions
1:sorafenib 600mg p.o bid
2:sunitinib 50mg p.o qd
3:Everolimus 10mg p.o qd
4:Everolimus 10mg p.o qd
Sponsors
Fudan University Shanghai Cancer Center
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. all patients with histologically confirmed RCC that was metastatic or unresectable and measurable according to Response Evaluation Criteria in Solid Tumors(RECIST1.0); 2. patients who was treated with routine dosage of sorafenib but failed; 3. male or female, age 18-75; 4. Patients were required to have an Eastern Cooperative Oncology Group performance status (ECOGPS) of =1.5*10^9/L, platelet count >=100*10^9/L, creatinine <=upper limit of normal, and total bilirubin <=1.5*upper limit of normal.
Exclusion criteria
Exclusion criteria: 1. have been treated with anti-angiogenic therapy other than sorafenib; 2. With other malignancies (except cured basal cell skin cancer or Cervical carcinoma in situ); 3. factors which will influence oral taking of drugs, for example: bad compliance, chronic diarrhea; 4. With other serious diseases, such as: unstable heart disease, severe cerebral vascular disease; 5. severe neurological or phycological disorders; 6. Other anti-tumor treatment or drugs applied simultaneously.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival;Objective response rate;Disease control rate;Adverse drug reaction;Quality of life; | — |
Countries
China
Contacts
Public ContactYe Dingwei
Outcome results
None listed